Mr. Jiang is a founding partner and CEO of Shanghai Yafo Capital and Co-CEO of Cukierman-Yafo Investment. He has over 15 years’ Wall Street experience in investment banking, M&A, and investment of in both Israeli and American technology companies. He has worked with US and China investment banks. He was the Chinese General Manager of ISI Group (NY) and Managing Director of ISI research. Before that, he was a senior research analyst at Roth Capital (LA) where he was involved in multiple cross-border transactions. When at Xiangcai Securities, a leading investment bank in Shanghai, Sean was the executive director, responsible for advising foreign institutional investors in China’s stock markets.
Mr. Jiang is now a visiting professor at Concordia University(Wisconsin). He received his MBA from Pepperdine University, MA in finance from Fudan University, and BA in Economics from Central South University of China. He is a CFA Charter holder.
Mr. Ravid was engaged in over $1B transactions over the past years, pioneering transactions such as taking the first Croatian company public on AIM, and completing the sale of first Telecom Hungarian based Nasdaq listed company. Mr. Ravid was a partner at MBI, an Investment House which jointly with Israel Industrial and Development Bank, invested in Israeli technology companies. Mr. Ravid sits on the board of a variety of technology companies. Mr. Ravid graduated Cum Laude from the Hebrew University and has a MBA from Rutgers University.
Mr. Tao is a Managing Partner of Yafo Capital and the Head of our U.S. Business. Mr. Tao has more than 15 years’ experience as an analyst and consultant working with public and private companies in North America and China across a variety of technology sectors. He has extensive knowledge on market analysis, business development, due diligence, and operations for U.S. – China cross-border transactions. He previously worked at William O’neil + Co. where he developed its Chinese operations and oversaw Chinese research. Before that, he was Director of Chinese research and senior research analyst at Roth Capital Partners where he supported over $2 billion cross-border equity financings.
Mr. Tao is a CFA Charter holder and has a MBA from University of California, Riverside.
Mr. Yao Nengong was graduated from Medical College of Shanghai JiaoTong University in 1990. After two years of being an OB doctor, Mr. Yao entered the field of medical care in China from 1993. Before he joints in Yafo capital, he has worked 7 years (1993-2000) in Astra China, which was the predecessor of AstraZeneca China, and was in charge of government affair, marketing and BD in China. Also he has co-established the Cyberpharm Investment Co., Ltd. and Sino-Octa Holdings Limited, which are focusing on the medical care field in China. He is responsible for the Sales and Marketing and BD in the company.
Mr. Cai has more than 20 years’ experience in investment banking. He had working and project experience with multiple security companies including XIANGCAI Securities, SouthWest Securities, Soochow Securities, KAIYUAN Securities. He led the acquisition between Baihe Network and Jiayuan,com., two leading match-making websites in China. Other projects he led are: refinance of Zhangjiagang Freetrade Science & Technology Group, IPO of Bank of Nanjing, and issuing the ABS of Sound Group etc.
Mr. Peng has been engaged in Chinese-Israeli technology cooperation and investment projects, he has comprehensive and deep cooperations with Israeli investment institutes, technology companies, and governmental organizations.
Mr. Zheng is the Managing Director of Yafo Capital. He has been focusing on cross-border investment in healthcare sector since the beginning of his career life. Mr. Zheng has been involved in 30+ global life science financing transactions and advisory assignments and has led the team to close numerous deals. Before joining Yafo Capital, He was an equity research analyst covering the Chinese healthcare sector at Roth Capital Partners, a full-service investment banking firm headquartered in California. He was also a founder of a medical device startup focusing on E.N.T related medical devices.
Miss Fang has been focusing on data analysis for 5+ years. She worked in Roche R&D AP and Nielsen Analytics, dealing with data management. Before Joining Yafo, she was an equity research analyst in life science sector in ABG Sundal Collier, a full-service Investment banking in Europe. During the academic research period, Xin was also involved in the statistical analysis in several Epidemiology studies, mainly in model development and applications.
Dr. Choppe has been involved in more than 50 medtech and biotech corporate finance transactions and advisory assignments. Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD (Fontainebleau, France). He is married, father of 3, and lives in Lausanne (Switzerland).
Mr. Topor specializes in a variety of clean tech industrial sub-sectors including: agriculture, renewable & alternative energy, energy efficiency, recycling & waste, and water technologies. He has been advising clients from North America, Europe, and Asia on a wide spectrum of financial transactions and deals.
COO, Yafo-Tech Discovery
CTO, Yafo-Tech Discovery
Analyst, Clean Tech team
Analyst, Investor Relations
Chairman, MCA, Yafo
Executive vice president, MCA; and Director of Yafo
CEO, Yafo-Herui Group
Chairman, Golden Sage Holding Group.